Login to Your Account

Cleave lands $37M series B financing

By Michael Fitzhugh
Staff Writer

Monday, August 8, 2016

Cleave Biosciences Inc. has completed a $37 million series B financing to support further development of CB-5083, its lead oncology candidate for hematological and solid tumor malignancies and discovery efforts related to its AAA ATPase platform over the next 18 months.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription